These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24997753)

  • 1. Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson's disease and Atypical Parkinsonian syndromes using DaTSCAN® SPECT.
    Davidsson A; Georgiopoulos C; Dizdar N; Granerus G; Zachrisson H
    Ann Nucl Med; 2014 Nov; 28(9):851-9. PubMed ID: 24997753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease.
    Kahraman D; Eggers C; Schicha H; Timmermann L; Schmidt M
    J Neurol; 2012 Feb; 259(2):251-60. PubMed ID: 21750954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 123I-FP-CIT SPECT imaging of the dopaminergic state. Visual assessment of dopaminergic degeneration patterns reflects quantitative 2D operator-dependent and 3D operator-independent techniques.
    Kahraman D; Eggers C; Holstein A; Schneider C; Pedrosa DJ; Dietlein M; Kobe C; Timmermann L; Schmidt M
    Nuklearmedizin; 2012; 51(6):244-51. PubMed ID: 22526237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes.
    Georgiopoulos C; Davidsson A; Engström M; Larsson EM; Zachrisson H; Dizdar N
    J Neurol; 2015 Sep; 262(9):2154-63. PubMed ID: 26122543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computed-tomography-guided anatomic standardization for quantitative assessment of dopamine transporter SPECT.
    Yokoyama K; Imabayashi E; Sumida K; Sone D; Kimura Y; Sato N; Mukai Y; Murata M; Matsuda H
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):366-372. PubMed ID: 27544223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 123I-FP-CIT brain SPECT (DaTSCAN) imaging in the diagnosis of patients with movement disorders--first results.
    Jauković L; Ilić TV; Dopudja M; Ajdinović B
    Vojnosanit Pregl; 2012 Feb; 69(2):157-62. PubMed ID: 22500370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
    Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
    Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study.
    Pirker W; Djamshidian S; Asenbaum S; Gerschlager W; Tribl G; Hoffmann M; Brücke T
    Mov Disord; 2002 Jan; 17(1):45-53. PubMed ID: 11835438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine transporter imaging (123)I-FP-CIT (DaTSCAN) SPET in differential diagnosis of dopa-responsive dystonia and young-onset Parkinson's disease.
    Brajkovic LD; Svetel MV; Kostic VS; Sobic-Saranovic DP; Pavlovic SV; Artiko VM; Obradovic VB
    Hell J Nucl Med; 2012; 15(2):134-8. PubMed ID: 22833860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson's disease?
    Gerasimou G; Costa DC; Papanastasiou E; Bostanjiopoulou S; Arnaoutoglou M; Moralidis E; Aggelopoulou T; Gotzamani-Psarrakou A
    Ann Nucl Med; 2012 May; 26(4):337-44. PubMed ID: 22382608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline [(123) I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease.
    Nissen T; Malek N; Grosset KA; Newman EJ; Patterson J; Hadley D; Grosset DG
    Acta Neurol Scand; 2014 Mar; 129(3):204-8. PubMed ID: 23962145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease.
    Benítez-Rivero S; Marín-Oyaga VA; García-Solís D; Huertas-Fernández I; García-Gómez FJ; Jesús S; Cáceres MT; Carrillo F; Ortiz AM; Carballo M; Mir P
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):122-9. PubMed ID: 22906618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discriminating among degenerative parkinsonisms using advanced (123)I-ioflupane SPECT analyses.
    Badoud S; Van De Ville D; Nicastro N; Garibotto V; Burkhard PR; Haller S
    Neuroimage Clin; 2016; 12():234-40. PubMed ID: 27489771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2006 Apr; 27(4):381-6. PubMed ID: 16531926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single photon emission computed tomography striatal asymmetry index may predict dopaminergic responsiveness in Parkinson disease.
    Contrafatto D; Mostile G; Nicoletti A; Raciti L; Luca A; Dibilio V; Lanzafame S; Distefano A; Drago F; Zappia M
    Clin Neuropharmacol; 2011; 34(2):71-3. PubMed ID: 21406999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease.
    Stoffers D; Booij J; Bosscher L; Winogrodzka A; Wolters EC; Berendse HW
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):689-95. PubMed ID: 15682332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.
    Gerschlager W; Bencsits G; Pirker W; Bloem BR; Asenbaum S; Prayer D; Zijlmans JC; Hoffmann M; Brücke T
    Mov Disord; 2002 May; 17(3):518-23. PubMed ID: 12112200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations between dopamine transporter density measured by
    Maekawa T; Sato N; Ota M; Sugiyama A; Sone D; Enokizono M; Kimura Y; Mukai Y; Murata M; Takano H; Imabayashi E; Matsuda H; Kunimatsu A; Abe O
    Jpn J Radiol; 2017 Dec; 35(12):755-759. PubMed ID: 29063467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
    Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
    Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
    Thobois S; Guillouet S; Broussolle E
    Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.